Summary
The product Anavar, manufactured by Vulkan Pharmaceuticals, underwent independent testing to verify its authenticity and potency. The sample, identified by batch number 9KT30G, was submitted by Vulkan Pharmaceuticals (vulkanpharma@proton.me) and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis measured the presence of Oxandrolone, with a concentration of 8.86 mg per tablet, which is 11.4% below the standard 10 mg per tablet claim.
The testing process began on 29 October 2024, with the sample received on 5 November 2024, and analysis completed on 13 November 2024. While the product contains the stated active ingredient, the measured dosage suggests a slight underdose. Independent third-party testing remains crucial for validating consistency across multiple batches. This report serves as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Vulkan Pharmaceuticals
- Product Name: Anavar Oxandrolone
- Active Ingredient: Oxandrolone
- Batch Number: 9KT30G
- Expiration Date: Not provided
- Dosage Form: Oral
Sample Acquisition and Testing
- Task Number: #52513
- Testing Ordered: 29 October 2024
- Sample Received: 5 November 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Vulkan Pharmaceuticals (Manufacturer)
- Analysis Paid For By: Vulkan Pharmaceuticals (Manufacturer)
Testing Results
- Specification: 10 mg per tablet (as stated on the label)
- Measured Concentration: 8.86 mg per tablet
- Accuracy: 88.6% (11.4% below the label claim)
- Variance: -11.4%
Verification Details
- Verification URL: https://janoshik.com/tests/52513_39T9E7WDT6CF
Evaluation of Manufacturer-Submitted Testing
This analysis confirms the presence of Oxandrolone, but the measured concentration is 11.4% below the label claim. Manufacturer-submitted samples often represent selected batches that may not fully reflect product consistency. While Janoshik Analytical maintains rigorous testing standards, independent validation through third-party testing is necessary to ensure uniform quality.
Conclusion
The analysis confirms that Anavar contains 8.86 mg per tablet, indicating a slight underdose compared to the expected 10 mg per tablet claim. While this remains within an acceptable variance for some users, consistency concerns should be addressed with additional testing. This report is provided to support educational and harm reduction efforts, helping consumers make informed decisions about anabolic steroid products.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-submitted testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
